On August 22, 2025, Plus Therapeutics, Inc. confirmed compliance with Nasdaq's listing rules, maintaining a market value of at least $35 million and stockholders' equity of at least $2.5 million, thus gaining an extension until November 12, 2025, to meet the $1.00 bid price rule.